These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
128 related items for PubMed ID: 1699780
1. In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis. Skirboll S, Wang J, Mefford I, Hsiao J, Bankiewicz KS. Exp Neurol; 1990 Nov; 110(2):187-93. PubMed ID: 1699780 [Abstract] [Full Text] [Related]
2. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Gerhardt GA, Cass WA, Huettl P, Brock S, Zhang Z, Gash DM. Brain Res; 1999 Jan 30; 817(1-2):163-71. PubMed ID: 9889359 [Abstract] [Full Text] [Related]
3. In vivo electrochemical studies of dopamine overflow and clearance in the striatum of normal and MPTP-treated rhesus monkeys. Gerhardt GA, Cass WA, Hudson J, Henson M, Zhang Z, Ovadia A, Hoffer BJ, Gash DM. J Neurochem; 1996 Feb 30; 66(2):579-88. PubMed ID: 8592127 [Abstract] [Full Text] [Related]
4. Tremor is associated with PET measures of nigrostriatal dopamine function in MPTP-lesioned monkeys. Eberling JL, Pivirotto P, Bringas J, Bankiewicz KS. Exp Neurol; 2000 Oct 30; 165(2):342-6. PubMed ID: 10993693 [Abstract] [Full Text] [Related]
5. Neurochemical changes in the substantiae nigrae and caudate nuclei following acute unilateral intranigral infusions of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Sirinathsinghji DJ, Whittington PE, Audsley AR. Brain Res; 1986 Dec 10; 399(2):339-45. PubMed ID: 2435361 [Abstract] [Full Text] [Related]
6. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. Oiwa Y, Eberling JL, Nagy D, Pivirotto P, Emborg ME, Bankiewicz KS. Front Biosci; 2003 Sep 01; 8():a155-66. PubMed ID: 12957824 [Abstract] [Full Text] [Related]
7. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys. Miletich RS, Bankiewicz KS, Quarantelli M, Plunkett RJ, Frank J, Kopin IJ, Di Chiro G. Ann Neurol; 1994 Jun 01; 35(6):689-97. PubMed ID: 8210225 [Abstract] [Full Text] [Related]
8. Xenotransplantation of microencapsulated bovine chromaffin cells into hemiparkinsonian monkeys. Xue YL, Wang ZF, Zhong DG, Cui X, Li XJ, Ma XJ, Wang LN, Zhu K, Sun AM. Artif Cells Blood Substit Immobil Biotechnol; 2000 Jul 01; 28(4):337-45. PubMed ID: 10928703 [Abstract] [Full Text] [Related]
9. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration. Pérez-Otaño I, Oset C, Luquin MR, Herrero MT, Obeso JA, Del Río J. Neurosci Lett; 1994 Jul 04; 175(1-2):121-5. PubMed ID: 7970192 [Abstract] [Full Text] [Related]
15. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Irwin I, DeLanney LE, Forno LS, Finnegan KT, Di Monte DA, Langston JW. Brain Res; 1990 Oct 29; 531(1-2):242-52. PubMed ID: 1981162 [Abstract] [Full Text] [Related]
17. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. Pifl C, Schingnitz G, Hornykiewicz O. Neurosci Lett; 1988 Oct 05; 92(2):228-33. PubMed ID: 3263594 [Abstract] [Full Text] [Related]
18. Effects of bifemelane on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Nomoto M, Irifune M, Fukuzaki K, Fukuda T. Neurosci Lett; 1994 Aug 29; 178(1):95-8. PubMed ID: 7816348 [Abstract] [Full Text] [Related]
19. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys. Alexander GM, Schwartzman RJ, Brainard L, Gordon SW, Grothusen JR. Brain Res; 1992 Aug 21; 588(2):261-9. PubMed ID: 1356591 [Abstract] [Full Text] [Related]